reports
- GlobalData Healthcare Department
Zynerba Pharmaceuticals Inc (ZYNE) - Financial Analysis Review
Zynerba Pharmaceuticals Inc (ZYNE) - Financial Analysis Review Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. GlobalData's Zynerba Pharmaceuticals In...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.